Compare IPW & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPW | BLRX |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 12.6M |
| IPO Year | 2021 | 2011 |
| Metric | IPW | BLRX |
|---|---|---|
| Price | $7.51 | $2.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 135.2K | 25.8K |
| Earning Date | 02-12-2026 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,151,725.00 | $12,735,000.00 |
| Revenue This Year | $149.67 | N/A |
| Revenue Next Year | $15.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.90 | $2.30 |
| 52 Week High | $34.65 | $14.70 |
| Indicator | IPW | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.01 | 38.99 |
| Support Level | $10.01 | $2.81 |
| Resistance Level | $12.01 | $3.10 |
| Average True Range (ATR) | 1.28 | 0.18 |
| MACD | -0.43 | -0.01 |
| Stochastic Oscillator | 0.42 | 16.56 |
iPower Inc is a United States-based online retailer and supplier of consumer home, pet, garden, outdoor, and consumer electronics products. It also operates as a provider of value-added ecommerce services for third-party products and brands. The company's capabilities include a spectrum of online channels, fulfillment capacity, a network of warehouses serving the U.S., last-mile delivery partners, and a differentiated business intelligence platform. The company's sales channels currently include Amazon Vendor, Amazon 3P, Walmart.com, TikTok, Temu, and other marketplaces, as well as its own e-commerce websites, such as simpledeluxe.com and more. Additionally, it is developing in-house branded products and through supply chain partners, which include iPower, Simple Deluxe, and other brands.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.